Hunan Er Kang Pharmaceutical Tangible Net Worth Ratio
Hunan Er Kang Pharmaceutical tangible net worth ratio. Hunan Er Kang Pharmaceutical (300267) has a Tangible Net Worth Ratio of 92.0% as of June 2025. This metric is calculated by deducting intangible assets (CN¥353.85 Million) from net assets (CN¥4.42 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Check 300267 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Hunan Er Kang Pharmaceutical (2008–2024)
Tangible net worth ratio of Hunan Er Kang Pharmaceutical from 2008 to 2024. This chart shows how Hunan Er Kang Pharmaceutical's Tangible Net Worth Ratio has changed across 17 annual periods from 2008 to 2024. As of June 2025, the ratio stands at 92.0%, reflecting net assets of CN¥4.42 Billion with intangible assets of CN¥353.85 Million CNY. See how liquid is Hunan Er Kang Pharmaceutical's working capital to evaluate short-term liquidity relative to the company's equity base.
Hunan Er Kang Pharmaceutical Tangible Net Worth Ratio by Year (2008–2024)
Hunan Er Kang Pharmaceutical tangible net worth ratio by year from 2008 to 2024. The table below presents the year-by-year Tangible Net Worth Ratio for Hunan Er Kang Pharmaceutical from 2008 to 2024, covering 17 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see Hunan Er Kang Pharmaceutical (300267) market capitalisation.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 91.7% | CN¥4.40 Billion | CN¥363.56 Million | CN¥5.20 Billion | ▼ -0.4 pp |
| 2023 | 92.1% | CN¥4.81 Billion | CN¥378.03 Million | CN¥5.48 Billion | ▲ +0.2 pp |
| 2022 | 92.0% | CN¥5.05 Billion | CN¥406.14 Million | CN¥5.86 Billion | ▲ +0.8 pp |
| 2021 | 91.1% | CN¥4.87 Billion | CN¥431.45 Million | CN¥5.43 Billion | ▲ +0.2 pp |
| 2020 | 90.9% | CN¥5.79 Billion | CN¥525.23 Million | CN¥6.55 Billion | ▼ -2.5 pp |
| 2019 | 93.4% | CN¥5.79 Billion | CN¥382.56 Million | CN¥6.14 Billion | ▼ -2.1 pp |
| 2018 | 95.5% | CN¥5.64 Billion | CN¥254.67 Million | CN¥6.05 Billion | ▲ +0.4 pp |
| 2017 | 95.1% | CN¥5.41 Billion | CN¥265.93 Million | CN¥5.72 Billion | ▲ +0.1 pp |
| 2016 | 95.0% | CN¥5.24 Billion | CN¥263.92 Million | CN¥5.65 Billion | ▲ +0.3 pp |
| 2015 | 94.7% | CN¥4.26 Billion | CN¥225.93 Million | CN¥4.80 Billion | ▲ +6.2 pp |
| 2014 | 88.5% | CN¥1.68 Billion | CN¥192.41 Million | CN¥2.22 Billion | ▼ -9.0 pp |
| 2013 | 97.5% | CN¥1.33 Billion | CN¥32.83 Million | CN¥1.45 Billion | ▼ -0.9 pp |
| 2012 | 98.5% | CN¥1.16 Billion | CN¥17.86 Million | CN¥1.24 Billion | ▼ -0.2 pp |
| 2011 | 98.7% | CN¥1.06 Billion | CN¥13.74 Million | CN¥1.13 Billion | ▲ +10.6 pp |
| 2010 | 88.1% | CN¥176.62 Million | CN¥20.98 Million | CN¥295.77 Million | ▲ +6.7 pp |
| 2009 | 81.4% | CN¥110.01 Million | CN¥20.41 Million | CN¥185.73 Million | ▼ -1.7 pp |
| 2008 | 83.1% | CN¥63.01 Million | CN¥10.64 Million | CN¥122.38 Million | — |